Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

Bristol-Myers Squibb (BMS) building

Opdivo a breakthrough in kidney cancer, says FDA

BMSmoves closer to US approval of its checkpoint inhibitor cancer immunotherapy

Bristol-Myers Squibb (BMS) building

Opdivo plus Yervoy effective first-line in lung cancer

Study shows immuno-oncology agents work well together

- PMLiVE

AZ and Peregrine join forces on cancer trial

Another oncology deal for the company after a recent spate of deals

- PMLiVE

Oncology directions

With increasingly expensive cancer drugs, what price should be paid for innovation?

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

Roche Basel Switzerland

Roche buys gene sequencing firm

Swiss firm has been working with Kapa for two years but is now acquiring the company

- PMLiVE

FDA grants priority review for new Keytruda licence

Merck’s PD-1 drug being assessed for first-line melanoma patients

- PMLiVE

Novartis licenses cancer support drug from Aveo Oncology

Swiss firm buys into drug to alleviate a wasting syndrome that is seen in chronic patients

Roche Basel Switzerland

Roche’s PD-L1 drug shrinks lung tumours

Drug has already showed success in treating certain bladder cancer patients

- PMLiVE

Bionor gears up for ‘kick and kill’ HIV data

Could also be used in conjunction with Celgene's cancer drug Revlimid

- PMLiVE

J&J buys into Alligator’s immuno-oncology candidate

Will spend $700m on the early-stage cancer deal

Roche Basel Switzerland

Roche and AbbVie’s leukaemia drug set for filing by year-end

Blood cancer treatment venetoclax faces a tough market if approved

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links